On March 15, 2023 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported that Nathan Standifer Ph.D., Executive Director of Translational Science at Tempest, will present a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023 Spring Scientific Meeting taking place March 15-17, 2023 in Denver, CO and virtually (Press release, Tempest Therapeutics, MAR 15, 2023, View Source [SID1234628828]). The poster highlights biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, showing an association between observed clinical benefit and fatty acid oxidation perturbations and gene expression.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details:
Title: TPST-1120, a first-in-human peroxisome-proliferator activated receptor-alpha (PPAR-α) antagonist: scientific rationale, clinical activity and biomarker assessments
Date: Thursday, March 16, 2023
Time: 6:00 – 7:30 p.m. MT
Abstract Number: 78